No Data
No Data
Livzon Pharma (01513.HK) spent HKD 8.9895 million to repurchase 0.3664 million shares on July 12th.
On July 12, Livzon Pharma (01513.HK) announced that it bought back 0.3664 million shares for HKD 8.9895 million.
Livzon Pharma spent approximately 4.3043 million Hong Kong dollars to buy back 0.1783 million shares on July 11th.
Livzon Pharma (01513) announced that it will spend approximately HKD 43.043 million to repurchase 0.1783 million shares at a repurchase price of HKD 23.8-24.3 per share on July 11, 2024. On the same day, Livzon Pharma will spend approximately RMB 42.917 million to repurchase 0.12 million shares of A-shares at a repurchase price of RMB 35.65-35.85 per share.
Livzon Pharma (01513) spent approximately 4.3043 million Hong Kong dollars to repurchase 0.1783 million shares on July 11th.
Livzon Pharma (01513) announced that it will spend approximately HKD 4.3043 million to repurchase...
Livzon Pharma (01513.HK) repurchased 0.0672 million shares on July 10 for a total cost of HKD 1.605 million.
Livzon Pharma (01513.HK) announced on July 10th that it spent HKD 1.605 million to repurchase 0.0672 million shares at a repurchase price of HKD 23.75-24.15 per share.
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
No Data